Skip to content

Basket

You currently have no items in your basket.

Total (excl. vat) £0.00
View basket & checkout

Yashraj Biotechnology Limited

Yashraj Biotechnology Limited (YBL) established in 1999 strives to meet emerging needs in the diagnostic and pre-clinical drug discovery segment. Originating as a Native Antigen manufacturer, the company has focused their innovation and excellence in the in-vitro diagnostics (IVD) sector by offering comprehensive range of products and services that include their high quality induced pluripotent stem cells (iPSC) and primary dermal cells.

View All Yashraj Biotechnology Limited Products

With their focus on making a healthier world, YBLs are developing a very high-quality portfolio of human induced pluripotent stem cell (iPSC) and iPSC derived cardiomyocytes and hepatocytes as products and services dedicated to advancing the development of more physiologically relevant in vitro models for the creation of safer and effective disease therapies.

Whether it is developing simple monoculture models or intricate co-culture, they are at the forefront of harnessing the potential of iPSCs to drive innovation in research and drug discovery.

The iPSCs are derived from Peripheral Blood Mononuclear Cells (PBMC) of healthy individuals. The PBMCs are primed and reprogrammed using a non-integrating sendai virus vector, with iPSC lines showing full differentiation potential.

The authenticity of these iPSC lines adheres to the ISSCR Guidelines for Stem Cell Research and are therefore perfectly suited for differentiation as well as drug toxicity and efficacy screening projects. Further information on the development of their high quality iPSCs can be found in the Journal of Stem Cell Research, Vol 77, June 2024.

Key features of YBLs iPSC lines include:

  • Human iPSCs show distinct borders and well-defined edges and are comprised of cells with a large nucleus & less cytoplasm.
  • Genetic stability is inspected by karyotyping
  • Successful differentiation assessed through EB formation and presence of FOXA2, OTX2 and SOX17 for three-germline detection
  • Identity and purity are determined by % of OCT4, NANOG and SSEA-4 all showing above 99% purity
  • Identity verification is successfully determined by STR analysis
Key features of YBLs iPSC lines include:

YBL has also successfully developed highly specialised iPSC derived human cardiomyocytes and hepatocytes that have been well established for Drug Toxicity studies.

The iPSC derived Cardiomyocytes cells exhibit electrical activity and rhythmic contractions, closely mimicking the behaviour of mature cardiac cells. They display robust responses to gold-standard tool compounds, making them invaluable for acute and chronic drug testing. These cell lines are sensitive to cardiotoxic compounds, such as anthracyclines, TKIs, and hERG-trafficking modulators, underlining their significance in drug safety assessments. Furthermore, they maintain genomic expression patterns akin to adult human cardiac tissue.

The Cardiomyocytes have been used and tested under the Comprehensive In Vitro Proarrhythmic Assay (CiPA) paradigm to be a useful component of cardiac risk assessment in a sponsor’s drug development program.  

Due to their high sensitivity and beating efficiency of 80-90% they have been successfully validated in a European lab for cardiac risk assessments and have shown to surpass the beating capability in comparison to other iPSC derived cardiomyocytes with earlier beating response at day 14. 


See the CoA here

Product Code

Cell Lines by YBL

YBL-iPSC - Human- M1

 

 

Human Induced Pluripotent Stem Cells (iPSC)-Male 

 

YBL-iPSC - Human- M2

 

Human Induced Pluripotent Stem Cells (iPSC)- Male 

 

YBL-iPSC - Human- F

 

 

Human Induced Pluripotent Stem Cells (iPSC)-Female 

 

YBL-iPSC-Cardiomyocytes

 

Human iPSC derived Cardiomyocytes 

 

YBL-iPSC-Hepatocytes

 

Human iPSC derived Hepatocytes